{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:19:26Z","timestamp":1788535166135,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd012349.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000}}],"reference-count":285,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012349.pub3","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T14:24:38Z","timestamp":1678112678000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia"],"prefix":"10.1002","volume":"2023","author":[{"given":"Louise J","family":"Geneen","sequence":"additional","affiliation":[{"name":"Systematic Review Initiative; NHS Blood and Transplant; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Dor\u00e9e","sequence":"additional","affiliation":[{"name":"Systematic Review Initiative; NHS Blood and Transplant; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise J","family":"Estcourt","sequence":"additional","affiliation":[{"name":"Haematology\/Transfusion Medicine; NHS Blood and Transplant; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"issue":"11","key":"10.1002\/14651858.CD012349.pub3-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1182\/blood.V108.11.557.557","article-title":"A randomized controlled trial comparing the combination therapy of deferiprone (DFP) and desferrioxamine (DFO) versus DFP or DFO monotherapy in patients with thalassemia major","volume":"108","author":"Aydinok","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD012349.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3324\/haematol.2011.056317","article-title":"Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response","volume":"97","author":"Aydinok","year":"2012","journal-title":"Haematologica"},{"issue":"12","key":"10.1002\/14651858.CD012349.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.11414","article-title":"A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major","volume":"92","author":"Aydinok","year":"2007","journal-title":"Haematologica"},{"issue":"S1","key":"10.1002\/14651858.CD012349.pub3-BIB0004|cit4","first-page":"190","article-title":"A randomized controlled prospective clinical study comparing the combination therapy of deferiprone (L1) and desferrioxamine with L1 and DFO monotherapy in patients with thalassemia major","volume":"91","author":"Manz","year":"2006","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0005|cit5","unstructured":"Badawy S Hassan TH Hesham MA Badr MA Evaluation of iron chelation therapy in B-thalassemic patients in Zagazig University Hospital ASPHO abstracts (The American Society of Pediatric Hematology\/Oncology) 2010 54 6 799 800"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/bcpt.12695","article-title":"Clinical pharmacist-provided services in iron overloaded Beta-thalassemia major children; a new insight to patient care","volume":"120","author":"Bahnasawy","year":"2017","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub3-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.bcmd.2014.04.004","article-title":"Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial","volume":"53","author":"Calvaruso","year":"2014","journal-title":"Blood Cells, Molecules, and Diseases"},{"issue":"7","key":"10.1002\/14651858.CD012349.pub3-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/ajh.24024","article-title":"Deferiprone versus deferoxamine in thalassemia intermedia: results from a 5-year long-term Italian multicenter randomized clinical trial","volume":"90","author":"Calvaruso","year":"2015","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Vitrano A Calvaruso G Di Maggio G Romeo MA Cianciulli P Lai ME Deferiprone versus deferoxamine in thalassemia intermedia: results from 5-year long-term Italian multi-center randomized clinical trial 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California 2014","DOI":"10.1182\/blood.V124.21.1354.1354"},{"issue":"11 pt 1","key":"10.1002\/14651858.CD012349.pub3-BIB0010|cit10","first-page":"Abstract no: 26","article-title":"Randomised prospective evaluation of iron balance, chelation efficiency, urine excretion and NTBI progression with deferiprone (DFP) or deferoxamine (DFO) monotherapy or with combined DFP plus DFO","volume":"106","author":"Aydinok","year":"2005","journal-title":"Blood"},{"issue":"S1","key":"10.1002\/14651858.CD012349.pub3-BIB0011|cit11","first-page":"443","article-title":"18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B-thalassemia major","volume":"99","author":"Elalfy","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"10.1002\/14651858.CD012349.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ejh.12507","article-title":"Efficacy and safety of a novel combination of two oral chelators deferasirox\/deferiprone over deferoxamine\/deferiprone in severely iron overloaded young beta thalassemia major patients","volume":"95","author":"Elalfy","year":"2015","journal-title":"European Journal of Haematology"},{"issue":"21","key":"10.1002\/14651858.CD012349.pub3-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1182\/blood.V122.21.559.559","article-title":"Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with beta-thalassemia major","volume":"122","author":"Elalfy","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD012349.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00277-008-0471-2","article-title":"Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience","volume":"87","author":"El-Beshlawy","year":"2008","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0015|cit15","unstructured":"Study with deferiprone and\/or desferrioxamine in iron overloaded patients clinicaltrials.gov\/ct2\/show\/NCT00350662"},{"issue":"9","key":"10.1002\/14651858.CD012349.pub3-BIB0016|cit16","first-page":"1241","article-title":"A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia","volume":"91","author":"Galanello","year":"2006","journal-title":"Haematologica"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD012349.pub3-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1182\/blood.V104.11.3611.3611","article-title":"Safety and efficacy of alternate desferrioxamine and deferiprone compared to desferrioxamine alone in the treatment of iron overload in transfusion-dependent thalassemia patients","volume":"104","author":"Galanello","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.15171\/jcs.2019.022","article-title":"Effect of A mobile-phone mediated based education on self-care behaviors of patients with thalassemia major","volume":"8","author":"Gharaati","year":"2019","journal-title":"Journal of Caring Sciences\u00a0"},{"issue":"5","key":"10.1002\/14651858.CD012349.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.19082\/2425","article-title":"Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine","volume":"8","author":"Hassan","year":"2016","journal-title":"Electronic Physician"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012349.pub3-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"s25","DOI":"10.1002\/pbc.29060","article-title":"Safety and efficacy of deferiprone vs deferoxamine for transfusion-dependent anemias","volume":"68","author":"Elalfy","year":"2021","journal-title":"Pediatric Blood and Cancer"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012349.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1182\/blood-2021-148064","article-title":"Randomized controlled trial of the efficacy and safety of deferiprone: subgroup analysis of pediatric patients in iron-overloaded patients with sickle cell disease and other anemias","volume":"138","author":"Hamdy","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.HS9.0000821448.70992.5a","article-title":"Randomized controlled trial of the efficacy and safety of deferiprone: subgroup analysis of pediatric patients in iron-overloaded patients with sickle cell disease and other anemias","volume":"6","author":"Inusa","year":"2022","journal-title":"Hemasphere"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012349.pub3-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1182\/blood-2019-122062","article-title":"Randomized controlled trial of the efficacy and safety of deferiprone in iron-overloaded patients with sickle cell disease or other anemias","volume":"134","author":"Kwiatkowski","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub3-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/bloodadvances.2021004938","article-title":"Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label, noninferiority study","volume":"6","author":"Kwiatkowski","year":"2021","journal-title":"Blood Advances"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0025|cit25","unstructured":"Efficacy and safety of Ferriprox\u00ae in patients with sickle cell disease or other anemias (FIRST) clinicaltrials.gov\/ct2\/show\/results\/NCT02041299"},{"issue":"11","key":"10.1002\/14651858.CD012349.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"Abstract no: 57","DOI":"10.1182\/blood.V110.11.575.575","article-title":"Deferiprone versus sequential deferiprone-deferoxamine treatment in thalassemia major: a five years multicenter randomized clinical trial under the auspices of the society for the study of thalassemia and hemogobinopathies (SoST)","volume":"110","author":"Maggio","year":"2007","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0027|cit27","doi-asserted-by":"crossref","unstructured":"Maggio A Capra M Cuccia L Gagliardotto F Rigano P Calvaruso G Long-term use of deferiprone enhances significantly the left ventricular ejection function in thalassemia major Blood 2011 Abstract 5302 https:\/\/doi.org\/10.1182\/blood.V118.21.5302.5302","DOI":"10.1182\/blood.V118.21.5302.5302"},{"issue":"11","key":"10.1002\/14651858.CD012349.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"Abstract no: 38","DOI":"10.1182\/blood.V112.11.3885.3885","article-title":"Decrease of mortality during deferiprone treatments: results from a large randomised cohort of thalassemia major patients under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies","volume":"112","author":"Maggio","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0029|cit29","first-page":"Abstract no: 38","article-title":"Decrease of mortality during deferiprone treatments: results from a large randomised cohort of thalassemia major patients under the auspices of the Italian society for thalassemia and hemogobinopathies","volume":"112 Suppl","author":"Maggio","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD012349.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2009.07609.x","article-title":"Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial","volume":"145","author":"Maggio","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0031|cit31","unstructured":"Efficacy study of the use of sequential DFP-DFO versus DFP clinicaltrials.gov\/ct2\/show\/NCT00733811"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/03630269.2011.570674","article-title":"Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in thalassemia major patients","volume":"35","author":"Pantalone","year":"2011","journal-title":"Hemoglobin"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0033|cit33","unstructured":"Multicentre, randomised, open label, non-inferiority active-controlled trial to evaluate the efficacy and safety of deferiprone compared to deferasirox in paediatric patients aged from 1 month to less than 18 years of age affected by transfusion-dependent haemoglobinopathies www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-000353-31\/IT"},{"issue":"6","key":"10.1002\/14651858.CD012349.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S2352-3026(20)30100-9","article-title":"Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial","volume":"7","author":"Maggio","year":"2020","journal-title":"Lancet Haematology"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0035|cit35","unstructured":"Multicentre, randomised, open label, non-inferiority active-controlled trial to evaluate the efficacy and safety of deferiprone compared to deferasirox in paediatric patients aged from 1 month to less than 18 years of age affected by transfusion-dependent haemoglobinopathies clinicaltrials.gov\/ct2\/show\/NCT01825512"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012349.pub3-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"Abstract 3552","DOI":"10.1182\/blood-2019-127933","article-title":"Neutropenia in children treated with deferiprone or deferasirox: a report of the largest randomized trial of oral chelators in transfusion-dependent pediatric patients","volume":"134","author":"Tricta","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2141.2003.04240.x","article-title":"Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients","volume":"121","author":"Mourad","year":"2003","journal-title":"British Journal of Haematology"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD012349.pub3-BIB0038|cit38","first-page":"651a","article-title":"Randomized trial of deferiprone (LI) and deferoxamine (DFO) in thalassemia major","volume":"88","author":"Olivieri","year":"1996","journal-title":"Blood"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD012349.pub3-BIB0039|cit39","first-page":"249a","article-title":"First prospective randomized trial of the iron chelators deferiprone (L1) and deferoxamine","volume":"86","author":"Olivieri","year":"1995","journal-title":"Blood"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD012349.pub3-BIB0040|cit40","first-page":"35b","article-title":"Evidence of progression of myocardial iron loading as determined by magnetic resonance imaging (MRI) in thalassemia patients during treatment with deferiprone (L1) and deferoxamine (DFO)","volume":"94","author":"Olivieri","year":"1999","journal-title":"Blood"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD012349.pub3-BIB0041|cit41","first-page":"264a","article-title":"Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO)","volume":"90","author":"Olivieri","year":"1997","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0042|cit42","volume-title":"Critical review of standard and new methods of assessing compliance with chelation therapy in thalassemic patients [thesis]","author":"Pope","year":"1995"},{"issue":"9","key":"10.1002\/14651858.CD012349.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","article-title":"Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis","volume":"107","author":"Pennell D","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1532-429X-13-34","article-title":"Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload","volume":"13","author":"Smith","year":"2011","journal-title":"Journal of Cardiovascular Magnetic Resonance"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/ejh.12487","article-title":"Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study","volume":"95","author":"Aydinok","year":"2015","journal-title":"European Journal of Haematology"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0046|cit46","unstructured":"Evaluating use of deferasirox AS compared to deferoxamine in treating cardiac iron overload clinicaltrials.gov\/show\/NCT00600938"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0047|cit47","first-page":"384","article-title":"Prevalence of cardiac iron overload in patients with transfusion-dependent anemias: data from the randomized, active-controlled deferasirox CORDELIA trial","volume":"97 Suppl 1","author":"Pennell","year":"2012","journal-title":"Haematologica"},{"issue":"21","key":"10.1002\/14651858.CD012349.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"Abstract no. 21","DOI":"10.1182\/blood.V120.21.2124.2124","article-title":"A multicenter, randomized, open-label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta-thalassemia major and iron overload (CORDELIA)","volume":"120","author":"Pennell","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1002\/14651858.CD012349.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1182\/blood.V122.21.1018.1018","article-title":"Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta-thalassemia major: 2-year data from the Cordelia extension","volume":"122","author":"Pennell","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD012349.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1182\/blood-2013-04-497842","article-title":"A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA)","volume":"123","author":"Pennell","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD012349.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ajh.23876","article-title":"Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine","volume":"90","author":"Pennell","year":"2015","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0052|cit52","unstructured":"A randomized, open-label, multicenter, two arm, phase II study to investigate the benefits of an improved deferasirox formulation (film-coated tablet) www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-004167-32\/IT"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0053|cit53","unstructured":"A randomized, open-label, multicenter, two arm, phase II study to investigate the benefits of an improved deferasirox formulation (film-coated tablet) www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-004167-32\/AT"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0054|cit54","doi-asserted-by":"crossref","unstructured":"Huang VW Banderas B Sen R Psychometric evaluation of clinical outcomes assessments in a phase II trial Value in Health 2016 19 7 A746","DOI":"10.1016\/j.jval.2016.09.2285"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0055|cit55","unstructured":"A randomized, open-label, multicenter, two arm, phase II study to investigate the benefits of an improved deferasirox formulation (film-coated tablet) clinicaltrials.gov\/ct2\/show\/NCT02125877"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012349.pub3-BIB0056|cit56","first-page":"s30","article-title":"Improved patient-reported outcomes with a film-coated versus dispersible tablet formulation of deferasirox: Results from the randomized, phase II eclipse study","volume":"64","author":"Taher","year":"2017","journal-title":"Pediatric Blood and Cancer\u00a0"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012349.pub3-BIB0057|cit57","first-page":"s30","article-title":"New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or MDS: results of the randomized, phase II eclipse study","volume":"64","author":"Taher","year":"2017","journal-title":"Pediatric Blood and Cancer\u00a0"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012349.pub3-BIB0058|cit58","first-page":"3508","article-title":"Predicting serum ferritin levels in patients with iron overload treated with the film-coated tablet of deferasirox during the eclipse study","volume":"130","author":"Taher","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD012349.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/ajh.24668","article-title":"New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: results of the randomized, Phase II ECLIPSE study","volume":"92","author":"Taher","year":"2017","journal-title":"American Journal of Hematology"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1002\/ajh.25408","article-title":"Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: a post hoc mediation analysis","volume":"94","author":"Taher","year":"2019","journal-title":"American Journal of Hematology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012349.pub3-BIB0061|cit61","first-page":"87","article-title":"Mediation by patient-reported outcomes on the association between film-coated versus dispersible formulations of deferasirox and serum ferritin reduction: a post hoc analysis of the eclipse trial","volume":"102","author":"Taher","year":"2017","journal-title":"Haematologica\u00a0"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012349.pub3-BIB0062|cit62","first-page":"45","article-title":"Mediation by patient-reported outcomes of the association between filmcoated or dispersible formulations of deferasirox and serum ferritin reduction: a post hoc analysis of the eclipse trial","volume":"27","author":"Taher","year":"2018","journal-title":"Pharmacoepidemiology and Drug Safety\u00a0"},{"issue":"8","key":"10.1002\/14651858.CD012349.pub3-BIB0063|cit63","first-page":"e443","article-title":"Improved patient-reported outcomes with a film-coated versus dispersible tablet formulation of deferasirox: results from the randomized, phase II eclipse study","volume":"92","author":"Taher","year":"2017","journal-title":"\u00a0American Journal of Hematology"},{"issue":"22","key":"10.1002\/14651858.CD012349.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"Abstract 1285","DOI":"10.1182\/blood.V128.22.1285.1285","article-title":"New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or MDS: Results of the randomized, phase II E.C.L.I.P.S.E. study","volume":"128","author":"Taher","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1002\/14651858.CD012349.pub3-BIB0065|cit65","first-page":"e346","article-title":"New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or myelodysplastic syndromes: results of the randomized, phase ii eclipse study","volume":"92","author":"Taher","year":"2017","journal-title":"American Journal of Hematology"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12955-018-1041-5","article-title":"Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias","volume":"16","author":"Taher","year":"2018","journal-title":"Health & Quality of Life Outcomes"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1002\/ajh.25322","article-title":"Predicting serum ferritin levels in patients with iron overload treated with the film-coated tablet of deferasirox during the ECLIPSE study","volume":"94","author":"Taher","year":"2019","journal-title":"American Journal of Hematology"},{"issue":"11","key":"10.1002\/14651858.CD012349.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"Abstract no. 17","DOI":"10.1182\/blood.V108.11.1770.1770","article-title":"Improved endothelial function combined chelation therapy in thalassaemia major","volume":"108","author":"Tanner","year":"2006","journal-title":"Blood"},{"issue":"14","key":"10.1002\/14651858.CD012349.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","article-title":"A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance","volume":"115","author":"Tanner","year":"2007","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0070|cit70","unstructured":"Tanner MA Galanello R Dessi C Smith GC Westwood MA Agus A The effect of combined therapy with deferoxamine and deferiprone on myocardial iron and endothelial function in thalassaemia major: a randomized controlled trials using cardiovascular magnetic resonance Haematologica 2006 91 Suppl 1 191"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD012349.pub3-BIB0071|cit71","first-page":"Abstract no. 36","article-title":"A randomized, placebo controlled, double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance","volume":"106","author":"Tanner","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2141.2011.08720.x","article-title":"Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease","volume":"154","author":"Vichinsky","year":"2011","journal-title":"British Journal of Haematology"},{"issue":"21","key":"10.1002\/14651858.CD012349.pub3-BIB0073|cit73","first-page":"Abstract no. 84","article-title":"Long-term safety and efficacy of deferasirox (Exjade\u00ae) in transfused patients with sickle cell disease treated for up to 5 years","volume":"118","author":"Vichinsky","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0074|cit74","unstructured":"Vichinsky E Coates T Thompson A Bernaudin F Lagrone D Dong V Safety and efficacy of iron chelation therapy with deferasirox in patients with sickle cell disease (SCD): 3.5-year follow-up 14th Congress of the European Haematology Association; Jun 4-7; Berlin, Germany 2009"},{"issue":"11","key":"10.1002\/14651858.CD012349.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"Abstract no. 14","DOI":"10.1182\/blood.V112.11.1420.1420","article-title":"Deferasirox (Exjade\u00ae), the once-daily oral iron chelator, demonstrates safety and efficacy in patients with sickle cell disease (SCD): 3.5-year follow-up","volume":"112","author":"Vichinsky","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0076|cit76","doi-asserted-by":"crossref","unstructured":"Vichinsky E Coates T Thompson AA Bernaudin F Rodriguez M Rojkjaer L Deferasorix (Exjade\u00ae), the once-daily oral iron chelator, demonstrates safety and efficacy in patients with sickle cell disease (SCD): 3.5-year follow-up 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; Feb 18-20; Florida, USA 2009","DOI":"10.1182\/blood.V112.11.1420.1420"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD012349.pub3-BIB0077|cit77","first-page":"995A","article-title":"Long-term efficacy and safety of deferasirox (Exjade\u00ae, ICL670), a once-daily oral iron chelator, in patients with sickle cell disease (SCD)","volume":"110","author":"Vichinsky","year":"2007","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"Abstract no. 31","DOI":"10.1182\/blood.V106.11.313.313","article-title":"A randomized, controlled phase two trial in sickle cell disease patients with chronic iron overload demonstrates that the once-daily oral iron chelator deferasirox (Exjade\u00ae, ICL670) is well tolerated and reduces iron burden","volume":"106","author":"Vichinsky","year":"2005","journal-title":"Blood"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD012349.pub3-BIB0079|cit79","first-page":"Abstract no. 23","article-title":"Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): comparison between deferasirox (Exjade\u00ae, ICL670) and deferoxamine (DFO)","volume":"106","author":"Vichinsky","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2141.2006.06455.x","article-title":"A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease","volume":"136","author":"Vichinsky","year":"2007","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000125550","article-title":"Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial","volume":"119","author":"Vichinsky","year":"2008","journal-title":"Acta Haematologica"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0082|cit82","unstructured":"Vichinsky E Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade\u00ae, ICL670) or deferoxamine (DFO) 29th Annual Meeting of the National Sickle Cell Disease Program; April 8-12; Memphis, USA 2006"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0083|cit83","unstructured":"Vichinsky E Results of a randomized, controlled phase two trials of deferasirox (Exjade\u00ae, ICL670) in sickle cell disease patients with chronic overload 29th Annual Meeting of the National Sickle Cell Disease Program; April 8-12; Memphis, USA 2006"},{"issue":"5","key":"10.1002\/14651858.CD012349.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1179\/1607845414Y.0000000197","article-title":"Impact of educational programme regarding chelation therapy on the quality of life for B-thalassemia major children","volume":"20","author":"Abu","year":"2015","journal-title":"Hematology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD012349.pub3-BIB0085|cit85","first-page":"S73","article-title":"Therapeutic effects of deferoxamine and silymarin versus deferoxamine alone in beta-thalassemia major based on findings of liver MRI","volume":"17","author":"Adibi","year":"2012","journal-title":"Journal of Research in Medical Sciences"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"243","DOI":"10.58397\/ashkmdc.v22i4.139","article-title":"Comparison of the mean serum ferritin levels in thalassaemia major patients after giving deferasirox and deferoxamine","volume":"22","author":"Aftab","year":"2017","journal-title":"Annals Abbasi Shaheed Hospital & Karachi Medical & Dental College"},{"issue":"7","key":"10.1002\/14651858.CD012349.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3109\/08880018.2014.939792","article-title":"Predictors of non-adherence to follow-up visits and deferasirox chelation therapy among Jordanian adolescents with thalassemia major","volume":"31","author":"Al-Kloub","year":"2014","journal-title":"Pediatric Hematology and Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/ijn.12143","article-title":"Impact of psychosocial status and disease knowledge on deferoxamine adherence among thalassaemia major adolescents","volume":"20","author":"Al-Kloub","year":"2014","journal-title":"International Journal of Nursing Practice"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012349.pub3-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/j.jadohealth.2016.10.263","article-title":"Comprehensive structured transition program with dedicated transition navigator reduced lost to follow-up and improved medication adherence in adolescents and young adults with sickle cell disease and thalassemia","volume":"60","author":"Allemang","year":"2017","journal-title":"Journal of Adolescent Health\u00a0"},{"issue":"22","key":"10.1002\/14651858.CD012349.pub3-BIB0090|cit90","first-page":"317","article-title":"Comprehensive structured transition program with dedicated transition navigator reduced lost to follow-up and improved medication adherence in sickle cell disease and thalassemia adolescents and young adults\u00a0","volume":"128","author":"Allemang","year":"2016","journal-title":"\u00a0Blood"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.12688\/f1000research.25553.1","article-title":"Green tea influence on iron overload in thalassemia intermedia patients: a randomized controlled trial","volume":"9","author":"Al-Momen","year":"2020","journal-title":"F1000research"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2141.1995.tb05274.x","article-title":"Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators","volume":"91","author":"Al-Refaie","year":"1995","journal-title":"British Journal of Haematology"},{"issue":"10","key":"10.1002\/14651858.CD012349.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/MPH.0b013e3181b53363","article-title":"Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy","volume":"31","author":"Alvarez","year":"2009","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0094|cit94","volume-title":"Adherence and Quality of Life in Pediatric Sickle Cell Disease: A Pilot Mobile Health Intervention [PhD thesis]","volume":"10188954","author":"Anderson","year":"2017"},{"issue":"8","key":"10.1002\/14651858.CD012349.pub3-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"e27081","DOI":"10.1002\/pbc.27081","article-title":"Mobile health intervention for youth with sickle cell disease: Impact on adherence, disease knowledge, and quality of life","volume":"65","author":"Anderson","year":"2018","journal-title":"Pediatric Blood & Cancer\u00a0"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD012349.pub3-BIB0096|cit96","first-page":"Abstract no: 26","article-title":"Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis","volume":"106","author":"Angelucci","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0097|cit97","first-page":"159","article-title":"Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior","volume":"8","author":"Ansari","year":"2017","journal-title":"Caspian Journal of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub3-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"e60820","DOI":"10.5812\/ircmj.60820","article-title":"\u00a0The effect of a holistic care program on the reduction of iron over load in patients with beta-thalassemia major: a randomized clinical trial","volume":"20","author":"Arian","year":"2018","journal-title":"\u00a0Iranian Red Crescent Medical Journal"},{"issue":"21","key":"10.1002\/14651858.CD012349.pub3-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1182\/blood.V118.21.3152.3152","article-title":"Costs, persistence, and hospitalizations associated with the use of iron-chelating therapies in sickle cell disease in medicaid patients","volume":"118","author":"Armstrong","year":"2011","journal-title":"Blood"},{"issue":"22","key":"10.1002\/14651858.CD012349.pub3-BIB0100|cit100","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1288.1288","article-title":"A randomised 1 year study evaluating the impact of vitamin c supplementation on systemic iron parameters of iron overload in thalassemia major patients on long-term treatment with deferasirox","volume":"128","author":"Aydinok","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD012349.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"956","DOI":"10.37506\/mlu.v21i2.2808","article-title":"Impact of lifestyle modification module on adherence to therapeutic regimen of children and adolescents with beta thalassemia major","volume":"21","author":"Aziz","year":"2021","journal-title":"Medico-Legal Update"},{"issue":"2","key":"10.1002\/14651858.CD012349.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5958\/0974-9357.2014.00624.2","article-title":"Treatment adherence and quality of life of thalassemic children","volume":"6","author":"Bala","year":"2014","journal-title":"International Journal of Nursing Education"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012349.pub3-BIB0103|cit103","first-page":"Abstract no: 56","article-title":"Short-term impact of educational interventions on disease knowledge, illness perception and quality of life among Jamaican adolescents with sickle cell disease","volume":"64\u00a0","author":"Barton-Gooden","year":"2015","journal-title":"West Indian Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub3-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"12","DOI":"10.18502\/ijhoscr.v13i1.320","article-title":"The effect of a training program based on the PRECEDE-PROCEED model on lifestyle of adolescents with beta-thalassemia: a randomized controlled clinical trial","volume":"13","author":"Bazpour","year":"2019","journal-title":"International Journal of Hematology-Oncology and Stem Cell Research"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1749-6632.1989.tb24191.x","article-title":"Health care adherence of persons with sickle cell disease. The role of social support","volume":"565","author":"Belgrave","year":"1989","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/bcp.13134","article-title":"Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years","volume":"83","author":"Bellanti","year":"2017","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"9","key":"10.1002\/14651858.CD012349.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/jcph.708","article-title":"Sampling optimization in pharmacokinetic bridging studies: example of the use of deferiprone in children with beta-thalassemia","volume":"56","author":"Bellanti","year":"2016","journal-title":"Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/j.1552-4604.1995.tb04062.x","article-title":"Use of a eutectic mixture of local anesthetics for prolonged subcutaneous drug administration","volume":"35","author":"Berkovitch","year":"1995","journal-title":"Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub3-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5812\/msnj.101560","article-title":"The effect of group education on adaptive behaviors and caregiver burden in mothers of children with thalassemia major: a trial clinical study","volume":"9","author":"Biabani","year":"2020","journal-title":"Medical-Surgical Nursing Journal\u00a0"},{"issue":"7","key":"10.1002\/14651858.CD012349.pub3-BIB0110|cit110","first-page":"6627","article-title":"Comparison of thalassemia major adolescent cases when treated with deferasirox and deferoxamine in terms of mean level of ferritin serum","volume":"5","author":"Bin Ahmed","year":"2018","journal-title":"Indo American Journal of Pharmaceutical Sciences\u00a0"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub3-BIB0111|cit111","first-page":"173","article-title":"Different desferrioxamine usage in the patients with thalassemia major: a cost-effect analysis","volume":"21","author":"Canatan","year":"2004","journal-title":"Turkish Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2010-11-316646","article-title":"Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up","volume":"118","author":"Cappellini","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0113|cit113","unstructured":"Cappellini MD Quebe-Fehling E Pallaud C Dieterle F Porter JB Exploring the clinical utility of renal safety biomarkers during iron chelation therapy in patients with beta-thalassemia and other anemias Blood 2017 Suppl 1 https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.4762.4762"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub3-BIB0114|cit114","first-page":"6","article-title":"Can the availability of unrestricted financial support improve the quality of care of thalassemics in a center with limited resources? A single center study from India","volume":"3","author":"Chakrabarti","year":"2013","journal-title":"Thalassemia Reports"},{"issue":"2","key":"10.1002\/14651858.CD012349.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.5958\/0974-360X.2021.00186.4","article-title":"Deferiprone (Ferriprox) as newer iron chelator in thalassaemia major patients","volume":"14","author":"Chaudhary","year":"2021","journal-title":"Research Journal of Pharmacy and Technology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012349.pub3-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1182\/blood-2018-99-119030","article-title":"Real-world experience of switching from deferasirox dispersible to film-coated tablets: impact on adherence to chelation therapy, iron overload and renal function","volume":"132","author":"Cheesman","year":"2018","journal-title":"Blood"},{"issue":"95","key":"10.1002\/14651858.CD012349.pub3-BIB0117|cit117","first-page":"698","article-title":"T2*MRI - An effective tool to increase chelation compliance in thalassemia major","author":"Daar","year":"2010","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ctim.2017.08.007","article-title":"The impact of silymarin on antioxidant and oxidative status in patients with beta-thalassemia major: a crossover, randomized controlled trial","volume":"35","author":"Darvishi-Khezri","year":"2017","journal-title":"Complementary Therapies in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/ptr.5995","article-title":"Iron-chelating effect of silymarin in patients with \u03b2-thalassemia major: a crossover randomised control trial","volume":"32","author":"Darvishi-Khezri","year":"2018","journal-title":"Phytotherapy Research : PTR"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD012349.pub3-BIB0120|cit120","first-page":"761A","article-title":"Semi-quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion-dependent anemia","volume":"106","author":"Deugnier","year":"2005","journal-title":"Blood"},{"issue":"21","key":"10.1002\/14651858.CD012349.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood.V116.21.4274.4274","article-title":"Deferasirox improves liver pathology in beta-thalassemia patients with transfusional iron overload","volume":"116","author":"Deugnier","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0122|cit122","doi-asserted-by":"crossref","DOI":"10.17918\/etd-7406","volume-title":"The Relationship between Adherence Behaviors and Health-related Quality of Life in Youth with Sickle Cell Disease: Does Cognitive and Academic Functioning Moderate This Relationship? [Masters thesis]","author":"Ding","year":"2017"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012349.pub3-BIB0123|cit123","first-page":"131","article-title":"Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young patients with b-thalassemia major: a randomized prospective trial","volume":"100","author":"Elalfy","year":"2015","journal-title":"Haematologica"},{"issue":"21","key":"10.1002\/14651858.CD012349.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood.V124.21.4046.4046","article-title":"Role of vitamin C as an adjuvant therapy with different iron chelators in young beta-thalassemia major patients: safety and efficacy in relation to tissue Iron overload","volume":"124","author":"Elalfy","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/ejh.12594","article-title":"Role of vitamin C as an adjuvant therapy to different iron chelators in young beta-thalassemia major patients: efficacy and safety in relation to tissue iron overload","volume":"96","author":"Elalfy","year":"2016","journal-title":"European Journal of Haematology"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0126|cit126","doi-asserted-by":"crossref","unstructured":"Elalfy M Helal B Berdoukas V Tricta F Tarif M Awad H Adly A Safety and efficacy of early start with suboptimal dose of deferiprone in minimally transfused infants with transfusion dependent thalassemia: a randomized trial Haematologica 2017 102 138","DOI":"10.1002\/ajh.24966"},{"issue":"2","key":"10.1002\/14651858.CD012349.pub3-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/ajh.24966","article-title":"Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: a randomized controlled trial","volume":"93","author":"Elalfy","year":"2018","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0128|cit128","doi-asserted-by":"crossref","unstructured":"Elalfy MS Berdoukas V Tricta F Adly A Hazza N Awed H A randomized trial on the safety and efficacy of early start of iron chelation therapy with deferiprone in newly diagnosed children with transfusion dependent thalassemia Blood 2016 128 22","DOI":"10.1182\/blood.V128.22.1286.1286"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0129|cit129","unstructured":"An algorithm to start iron chelation in minimally transfused young beta-thalassemia major patients clinicaltrials.gov\/ct2\/show\/NCT02173951"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub3-BIB0130|cit130","first-page":"130","article-title":"Psychological therapies: the missing link in improving treatment adherence in patients with beta-thalassemia major","volume":"9","author":"Emami Zeydi","year":"2018","journal-title":"Iranian Journal of Blood and Cancer (Iranian Pediatric Hematology and Oncology Society)"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub3-BIB0131|cit131","first-page":"108","article-title":"The comparison of efficacy of original brand deferoxamine with generic iranian made deferoxamine in urinary iron excretion in patients with thalassemia major","volume":"9","author":"Eshghi","year":"2018","journal-title":"Iranian Journal of Blood and Cancer (Iranian Pediatric Hematology and Oncology Society)"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0132|cit132","unstructured":"A multicenter, randomized, open-label phase II trial evaluating deferasirox compared with deferoxamine in patients with cardiac iron overload due to chronic blood transfusions - ND EUCTR2007-000766-20-IT\u00a0"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0133|cit133","unstructured":"Evaluating the efficacy of Exjade\u00ae (deferasirox) in transfusion dependent chronic anaemias (myelodysplasia syndrome, beta-thalassaemia major patients) with chronic iron overload clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2007-004008-10"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0134|cit134","unstructured":"A study to evaluate the benefit and safety of Luspatercept (ACE-536) in adults with beta-thalassemia who do not require regular red blood cell tranfusions EUCTR2015-003225-33-GR\u00a0"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0135|cit135","first-page":"83","article-title":"Evaluation of effective factors in the acceptance of mobile health technology using the unified theory of acceptance and use of technology (UTAUT), case study: blood transfusion complications in thalassemia patients","volume":"34","author":"Farhady","year":"2020","journal-title":"Medical Journal of the Islamic Republic of Iran"},{"issue":"10","key":"10.1002\/14651858.CD012349.pub3-BIB0136|cit136","first-page":"1343","article-title":"Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major","volume":"91","author":"Galanello","year":"2006","journal-title":"Haematologica"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub3-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1177\/1054773813479377","article-title":"Evaluation of the SCKnowIQ tool and reproductive CHOICES intervention among young adults with sickle cell disease or sickle cell trait","volume":"23","author":"Gallo","year":"2014","journal-title":"Clinical Nursing Research"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub3-BIB0138|cit138","first-page":"21","article-title":"Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children","volume":"41","author":"Gomber","year":"2004","journal-title":"Indian Pediatrics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012349.pub3-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.1182\/blood-2018-99-110112","article-title":"Novel multidisciplinary comprehensive clinic program improves patient compliance, patient satisfaction and health maintainance outcomes in the outpatient setting for patients with severe sickle cell disease","volume":"132","author":"Gordon","year":"2018","journal-title":"Blood"},{"issue":"S2","key":"10.1002\/14651858.CD012349.pub3-BIB0140|cit140","first-page":"1","article-title":"Comparision of therapeutic effect of osveral & desferal in patients with thalassemia (Bahonar Hospital in Karaj 2012-2013)","volume":"24","author":"Habibian","year":"2014","journal-title":"Iranian Journal of Pediatrics (Tehran University of Medical Sciences)"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/1871526515666150731113305","article-title":"Therapeutic value of combined therapy with deferiprone and silymarin as iron chelators in Egyptian children with beta thalassemia major","volume":"15","author":"Hagag","year":"2015","journal-title":"Infectious Disorders Drug Targets"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/17425255.2020.1729353","article-title":"Recent insight on improving the iron chelation efficacy of deferasirox by adjuvant therapy in transfusion dependent beta thalassemia children with sluggish response","volume":"16","author":"Hamed","year":"2020","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"issue":"10","key":"10.1002\/14651858.CD012349.pub3-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"e713","DOI":"10.1016\/S2352-3026(20)30299-4","article-title":"Tackling adherence in sickle cell disease with mHealth","volume":"7","author":"Hankins","year":"2020","journal-title":"Lancet Haematology"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub3-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/bjh.17953","article-title":"Bridging the implementation gap in medication adherence. If you build it, will they come?","volume":"196","author":"Hankins","year":"2021","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.HS9.0000821428.51427.ac","article-title":"Long-term efficacy and safety of deferiprone for patients with sickle cell disease or other anemias","volume":"6","author":"Inusa","year":"2022","journal-title":"Hemasphere"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.htct.2021.10.040","article-title":"Long-term safety and efficacy of deferiprone for the treatment of chronically transfused, iron-overloaded patients with sickle cell disease or other anemias","volume":"43","author":"Verissimo","year":"2021","journal-title":"Hematology, Transfusion and Cell Therapy"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0147|cit147","unstructured":"The comparison of the efficacy of Iranian Deferasirox (Osveral\u00ae) and Exjade\u00ae on serum ferritin in patients with major beta-thalassemia en.irct.ir\/trial\/33699"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub3-BIB0148|cit148","first-page":"61","article-title":"Two trade names of deferasirox (Osveral\u00ae and Exjade\u00ae) in reduction of iron overload parameters in major betathalassemia patients: a randomized open labeled clinical trial","volume":"13","author":"Rafati","year":"2022","journal-title":"Caspian Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0149|cit149","unstructured":"Effect of storytelling on social, excited and education self-efficacy in children 7-12 years old with thalassemia in Mashhad trialsearch.who.int\/Trial2.aspx?TrialID=IRCT2015012914504N3"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0150|cit150","unstructured":"Treatment of iron overload in thalassemia patients: comparison of combined therapy with deferoxamine and deferiprone versus monotherapy with deferoxamine or deferiprone in iron overloaded thalassemia patients www.irct.ir\/trial\/22446"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0151|cit151","unstructured":"The effect of positive thinking education on parents of adolescents with thalassemia www.irct.ir\/trial\/32127"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0152|cit152","unstructured":"The effect of mobile phone-based education on patients with thalassemia https:\/\/www.irct.ir\/trial\/30609"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.phoj.2018.08.001","article-title":"Combination of two oral iron chelators in patients with thalassemia major","volume":"3","author":"Jhinger","year":"2018","journal-title":"Pediatric Hematology Oncology Journal (Pediatric Hematology Oncology Chapter of Indian Academy of Pediatrics)"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/ejh.13111","article-title":"Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes","volume":"101","author":"Kattamis","year":"2018","journal-title":"European Journal of Haematology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012349.pub3-BIB0155|cit155","first-page":"634","article-title":"A multicenter open-label study on the safety and acceptability of twice-daily deferiprone tablets among patients with transfusion-dependent thalassemia and systemic iron overload","volume":"5","author":"Kattamis","year":"2021","journal-title":"HemaSphere"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0156|cit156","volume-title":"Establishing initial data and assessing the feasibility of a community collaborative to improve adherence to essential management in beta-thalassemia patients in Pune, India [PhD thesis]","volume":"27832201","author":"Kejriwal","year":"2020"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1365-2141.2008.07234.x","article-title":"Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?","volume":"142","author":"Kidson-Gerber","year":"2008","journal-title":"British Journal of Haematology"},{"issue":"1-2","key":"10.1002\/14651858.CD012349.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/03630260701727085","article-title":"Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine\/deferiprone combination. Identification of effective chelation therapy protocols","volume":"32","author":"Kolnagou","year":"2008","journal-title":"Hemoglobin"},{"issue":"2","key":"10.1002\/14651858.CD012349.pub3-BIB0159|cit159","first-page":"21","article-title":"Comparative efficacy of deferrioxamin and combination of deferiprone and deferrioxamine on echocardiographic indices in beta thalassemic patients","volume":"14","author":"Kompany","year":"2009","journal-title":"Scientific Journal of Kurdistan University of Medical Sciences"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0160|cit160","doi-asserted-by":"crossref","unstructured":"Leonard S Jonassaint J Anderson L Shah N The use of mobile technology for intensive training in medication management in the pediatric population Blood 2014 124 21","DOI":"10.1182\/blood.V124.21.4842.4842"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub3-BIB0161|cit161","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/jpepsy\/jsv084","article-title":"Systematic and meta-analytic review: medication adherence among pediatric patients with sickle cell disease","volume":"41","author":"Loiselle","year":"2015","journal-title":"Journal of Pediatric Psychology\u00a0"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/jpepsy\/jsv084","article-title":"Systematic and meta-analytic review: medication adherence among pediatric patients with sickle cell disease","volume":"41","author":"Loiselle","year":"2016","journal-title":"Journal of Pediatric Psychology"},{"issue":"2","key":"10.1002\/14651858.CD012349.pub3-BIB0163|cit163","first-page":"170","article-title":"The effect of Orem self-care model on health-related quality of life of patients with thalassemia major","volume":"7","author":"Madmoli","year":"2019","journal-title":"Journal of Research in Medical and Dental Science"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0164|cit164","volume-title":"Study on comparison of efficacy and adverse effects of deferasirox vs deferiprone in treatment of iron overload in thalassemia [PhD thesis]","author":"Matti","year":"2013"},{"issue":"5","key":"10.1002\/14651858.CD012349.pub3-BIB0165|cit165","doi-asserted-by":"publisher","DOI":"10.1186\/1745-0179-5-5","article-title":"Emotional impact in beta-thalassaemia major children following cognitive-behavioural family therapy and quality of life of caregiving mothers","volume":"5","author":"Mazzone","year":"2009","journal-title":"Clinical Practice and Epidemiology in Mental Health"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0166|cit166","volume-title":"Parent Educational Intervention Program (PEIP) for Improving Parental Knowledge, Self-Efficacy, & Parent Perception of Health Related Quality of Life in Children with Sickle Cell Disease Using Smartphone Technology [PhD thesis]","author":"Mohamed Al Nasiri","year":"2018"},{"issue":"9","key":"10.1002\/14651858.CD012349.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/ptr.6118","article-title":"An investigation of the effects of curcumin on iron overload, hepcidin level, and liver function in beta-thalassemia major patients: a double-blind randomized controlled clinical trial","volume":"32","author":"Mohammadi","year":"2018","journal-title":"Phytotherapy Research : PTR"},{"issue":"3-4","key":"10.1002\/14651858.CD012349.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000479634","article-title":"Benefits of curcumin supplementation on antioxidant status in beta-thalassemia major patients: a double-blind randomized controlled clinical trial","volume":"71","author":"Nasseri","year":"2017","journal-title":"Annals of Nutrition & Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0169|cit169","first-page":"93","article-title":"Comparison of therapeutic response and complications of oral Osveral and injection Desfereal chelating agent in patient with thalassemia major","volume":"3","author":"Molavi","year":"2013","journal-title":"Asian Journal of Medical and Pharmaceutical Researches"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub3-BIB0170|cit170","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5829\/idosi.abr.2014.8.4.8546","article-title":"Combined desferrioxamine (Desferal) and deferasirox in children","volume":"8","author":"Molavi","year":"2014","journal-title":"Advances in Biological Research"},{"issue":"5","key":"10.1002\/14651858.CD012349.pub3-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"e3869","DOI":"10.5812\/ijp.3869","article-title":"The effects of nutrition, exercise, and a praying program on reducing iron overload in patients with beta-thalassemia major: a randomized clinical trial","volume":"26","author":"Molazem","year":"2016","journal-title":"Iranian Journal of Pediatrics"},{"issue":"9","key":"10.1002\/14651858.CD012349.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","article-title":"A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with \u03b2-thalassemia","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD012349.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1182\/blood-2007-08-109306","article-title":"Effect of transfusional iron intake on response to chelation therapy in \u03b2-thalassemia major","volume":"111","author":"Cohen","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0174|cit174","unstructured":"Safety & efficacy of ICL670 vs. deferoxamine in beta-thalassemia patients with iron overload due to blood transfusions https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00061750"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0175|cit175","unstructured":"Combination deferasirox and deferiprone for severe iron overload in thalassemia clinicaltrials.gov\/ct2\/show\/NCT01709032"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0176|cit176","unstructured":"Use of mobile technology for intensive training in medication management clinicaltrials.gov\/ct2\/show\/NCT02133560"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0177|cit177","unstructured":"Music therapy in sickle cell transition study clinicaltrials.gov\/ct2\/show\/NCT02466555"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0178|cit178","unstructured":"BEATS 2: music therapy in sickle cell clinicaltrials.gov\/ct2\/show\/NCT03233269"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0179|cit179","unstructured":"A study to determine the efficacy and safety of luspatercept in adults with non transfusion dependent beta (\u03b2)-thalassemia clinicaltrials.gov\/show\/NCT03342404"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0180|cit180","unstructured":"A study with LJPC-401 for the treatment of myocardial iron overload in adult patients with transfusion-dependent beta thalassemia clinicaltrials.gov\/ct2\/show\/NCT03381833"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.HS9.0000821460.57070.77","article-title":"Safety and efficacy of early-start deferiprone in infants and young children with beta-thalassemia (START study)","volume":"6","author":"Elalfy","year":"2022","journal-title":"Hemasphere"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2021-149359","article-title":"A prospective randomized multicenter trial using either deferiprone or deferasirox after an early start of deferiprone or placebo in young children newly diagnosed with transfusion-dependent beta-thalassemia","volume":"138","author":"Elalfy","year":"2021","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1182\/blood-2021-147595","article-title":"Safety and efficacy of early-start deferiprone in infants and young children with beta-thalassemia (START study)","volume":"138","author":"Elalfy","year":"2021","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0184|cit184","unstructured":"Safety and efficacy of early treatment with deferiprone in infants and young children clinicaltrials.gov\/ct2\/show\/NCT03591575"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0185|cit185","unstructured":"Pilot study to assess the safety, pk and iron chelating activity of DST-0509 (deferasirox) in thalassemia patients refractory to chelation clinicaltrials.gov\/ct2\/show\/NCT03637556"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0186|cit186","unstructured":"Phase 2a pilot study of NBMI treatment in patients with beta thalassemia major, requiring iron chelation clinicaltrials.gov\/ct2\/show\/NCT04092205"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0187|cit187","unstructured":"Hydroxy urea, omega 3, nigella sativa, honey on oxidative stress and iron chelation in pediatric major thalassemia clinicaltrials.gov\/ct2\/show\/NCT04292314"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0188|cit188","unstructured":"Medication adherence and non-adherence in adults with rare disease clinicaltrials.gov\/ct2\/show\/NCT04541875"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0189|cit189","unstructured":"An mHealth strategy to improve medication adherence in adolescents with sickle cell disease clinicaltrials.gov\/ct2\/show\/NCT04688411"},{"issue":"11","key":"10.1002\/14651858.CD012349.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"33B","DOI":"10.1182\/blood.V104.11.3787.3787","article-title":"Assessing compliance to iron chelation therapy in patients with thalassemia","volume":"104","author":"Pakbaz","year":"2004","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1196\/annals.1345.065","article-title":"A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia","volume":"1054","author":"Pakbaz","year":"2005","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"6","key":"10.1002\/14651858.CD012349.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1111\/bjh.16101","article-title":"Long-term sequential deferiprone and deferasirox therapy in transfusion-dependent thalassaemia patients: a prospective clinical trial","volume":"186","author":"Vitrano","year":"2019","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4103\/0974-8520.141898","article-title":"Efficacy of triphaladi avaleha on beejadushtijanya pandu (thalassemia)","volume":"35","author":"Patalia Abishek","year":"2014","journal-title":"Ayu"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub3-BIB0194|cit194","first-page":"55","article-title":"Comparison of deferasirox and deferoxamine treatment in iron-overloaded patients: liver iron concentration determined by quantitative MRI-R2*","volume":"47","author":"Peng","year":"2013","journal-title":"Chinese Journal of Radiology"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0195|cit195","first-page":"641","article-title":"Health- related quality of life, treatment satisfaction, adherence and persistence in beta-thalassemia and myelodysplastic syndrome patients with iron overload receiving deferasirox: results from the epic clinical trial","volume":"297","author":"Porter","year":"2012","journal-title":"Anemia"},{"issue":"22","key":"10.1002\/14651858.CD012349.pub3-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"poster 2486","DOI":"10.1182\/blood.V114.22.2486.2486","article-title":"Improved patient satisfaction, adherence and health-related quality of life with deferasirox (Exjade) in beta-thalassemia patients previously receiving other iron chelation therapies","volume":"114","author":"Porter","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0197|cit197","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1080\/03630269.2019.1651331","article-title":"Evaluation of the effect of support-training system of peer group on promotion of self-care in beta-thalassemia major patients in Southern Iran","volume":"43","author":"Safaei","year":"2019","journal-title":"Hemoglobin"},{"issue":"24","key":"10.1002\/14651858.CD012349.pub3-BIB0198|cit198","first-page":"4718","article-title":"Efficacy and safety of deferasirox when compared to deferiprone as oral iron chelating agent: a randomized control trial","volume":"4","author":"Sanjeeva","year":"2015","journal-title":"Journal of Evolution of Medical and Dental Sciences"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0199|cit199","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/08971900211038301","article-title":"Efficacy and tolerability of twice-daily dosing schedule of deferasirox in transfusion-dependent paediatric beta-thalassaemia patients: a randomized controlled study","volume":"online","author":"Panachiyil","year":"2022","journal-title":"Journal of Pharmacy Practice"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012349.pub3-BIB0200|cit200","first-page":"106","article-title":"Assessment of clinical outcome of twice daily dosing schedule of deferasirox in transfusion dependent paediatric beta thalassemia patients a randomized controlled study","volume":"29","author":"Sebastian","year":"2020","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"S47","key":"10.1002\/14651858.CD012349.pub3-BIB0201|cit201","doi-asserted-by":"publisher","first-page":"PIH17","DOI":"10.1016\/j.vhri.2020.07.244","article-title":"Efficacy, tolerability and medication adherence of twice-daily dosing schedule of deferasirox in transfusion-dependent paediatric beta thalassemia patients: a randomized controlled study","volume":"22","author":"Sebastian","year":"2020","journal-title":"Value in Health Regional Issues"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub3-BIB0202|cit202","first-page":"655","article-title":"Iron chelation therapy in beta-thalassemia major showing non-inferiority of oral chelator over parenteral chelator","volume":"40","author":"Shah","year":"2021","journal-title":"Latin American Journal of Pharmacy"},{"issue":"6","key":"10.1002\/14651858.CD012349.pub3-BIB0203|cit203","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/jpepsy\/jsaa031","article-title":"A systematic review of medication adherence interventions in pediatric sickle cell disease","volume":"45","author":"Shih","year":"2020","journal-title":"Journal of Pediatric Psychology"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub3-BIB0204|cit204","first-page":"27","article-title":"Adherence to iron chelation therapy and its determinants","volume":"15","author":"Sidhu","year":"2021","journal-title":"International Journal of Hematology Oncology & Stem Cell Research"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0205|cit205","volume-title":"Parent and adolescent factors related to adherence and health outcomes in sickle cell disease [PhD thesis]","author":"Smith","year":"2016"},{"issue":"2","key":"10.1002\/14651858.CD012349.pub3-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"107","DOI":"10.32598\/jpcp.7.2.107","article-title":"Acceptance and commitment therapy improves psychological flexibility of students with thalassemia major: a randomized controlled trial","volume":"7","author":"Souran","year":"2019","journal-title":"Journal of Practice in Clinical Psychology"},{"issue":"5","key":"10.1002\/14651858.CD012349.pub3-BIB0207|cit207","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1080\/03630269.2021.1999258","article-title":"Comparative efficacy and safety between deferiprone and deferasirox with special reference to serum ferritin level and cardiac function in Bengali beta-thalassemia major children","volume":"45","author":"Tripathy","year":"2021","journal-title":"Hemoglobin (International Journal for Hemoglobin Research)"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0208|cit208","unstructured":"A prospective study of treatment continuation rate with early low-dose iron chelation therapy for patients with transfusion-induced iron overload center6.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000009016"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD012349.pub3-BIB0209|cit209","first-page":"Abstract no. 23","article-title":"Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): comparison between deferasirox (Exjade\u00ae, ICL670) and deferoxamine (DFO)","volume":"106","author":"Vichinsky","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000125550","article-title":"Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial","volume":"119","author":"Vichinsky","year":"2008","journal-title":"Acta Haematologica"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0211|cit211","volume-title":"The feasibility of a medical student mentoring program to improve transition of care among young adults with sickle cell disease [PhD thesis]","author":"Viola","year":"2020"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0212|cit212","volume-title":"Novel approaches to iron chelation therapy: novel combinations and novel compounds [PhD thesis]","author":"Vlachodimitropoulou Koumoutsea","year":"2017"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0213|cit213","first-page":"297","article-title":"Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major","volume":"26","author":"Waheed","year":"2014","journal-title":"Journal of Ayub Medical College, Abbottabad: JAMC"},{"issue":"6","key":"10.1002\/14651858.CD012349.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1542\/peds.2014-0177","article-title":"Medication adherence among pediatric patients with sickle cell disease: a systematic review","volume":"134","author":"Walsh","year":"2014","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0215|cit215","volume-title":"Relationship between executive functioning and adherence in youth with sickle cell disease [PhD thesis]","author":"Wilson","year":"2016"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub3-BIB0216|cit216","first-page":"11","article-title":"Subcutaneous bolus injection of deferoxamine is an alternative method to subcutaneous continuous infusion","volume":"28","author":"Yarali","year":"2006","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub3-BIB0217|cit217","doi-asserted-by":"publisher","first-page":"47","DOI":"10.36106\/ijsr","article-title":"Efficacy of once a month single dose intravenous (deferoxamine) versus daily oral (deferasirox) iron chelator in thalassemia major: an open label randomized parallel group active control interventional trial","volume":"9","author":"Bhojak","year":"2020","journal-title":"International Journal of Scientific Research"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD012349.pub3-BIB0218|cit218","first-page":"S65","article-title":"Deferoxamine intravenous once a month injection single dose versus deferasirox oral daily: iron chelator in thalassemia major: an open label randomized parallel group active control interventional trial","volume":"36","author":"Bhojak","year":"2020","journal-title":"Indian Journal of Hematology & Blood Transfusion"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0219|cit219","unstructured":"A comparative trial to assess the efficacy of tablet deferasirox versus injection deferoxamine by reduction in serum ferritin level in pediatric thalassemia major patient in tertiary care hospital by prospective study ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=19387&EncHid=&userName=009441"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012349.pub3-BIB0220|cit220","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1182\/blood-2019-125875","article-title":"Feasibility of electronic monitoring of daily oral medications in adolescents with sickle cell disease","volume":"134","author":"Crosby","year":"2019","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0221|cit221","unstructured":"Efficacy of combination therapy with oral iron chelators in children with transfusion dependant beta-thalassemia major on assessing cardiac function by echocardiography and tissue doppler imaging- a hospital based open labelled randomised controlled trial trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2020\/07\/026771"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub3-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.transci.2019.03.021","article-title":"A 1-year randomized trial of deferasirox alone versus deferasirox and deferoxamine combination for the treatment of iron overload in thalassemia major","volume":"58","author":"Eghbali","year":"2019","journal-title":"Transfusion and Apheresis Science"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0223|cit223","unstructured":"The effect of Exjade and its combination therapy with Desferal is compared with the reduction of ferritin in patients with thalassemia major www.en.irct.ir\/trial\/18313"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0224|cit224","unstructured":"Clinical Trial Results: Proton pump inhibition for secondary hemochromatosis in hereditary anemia, a phase III placebo controlled randomized cross-over clinical trial https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-003777-34\/results"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0225|cit225","unstructured":"PPI in secondary hemochromatosis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2017-003777-34-NL"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0226|cit226","first-page":"713","article-title":"A cohort study to assess the contribution of patient compliance program on persistence to deferasirox in patients with chronic iron overload in Turkey (ex-pat program)","volume":"98","author":"Antmen","year":"2013","journal-title":"Haematologica\/the Hematology Journal"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0227|cit227","unstructured":"The effect of education base on empowering model on major thalassemia patients en.irct.ir\/trial\/13021"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0228|cit228","unstructured":"Comparison of the effect of deferasirox and deferiprone combination and defroxamine\/deferiprone regimen among patients with beta-thalassemia en.irct.ir\/trial\/22246"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0229|cit229","unstructured":"Compare the efficacy of combination deferasirox and deferiprone with deferoxamine and deferiprone in reducing heart and liver iron load in patients with transfusion-dpendent \u03b2-thalassemia www.irct.ir\/trial\/36668"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0230|cit230","unstructured":"The effect of group hope therapy on hope and adherence to treatment in adolescents with \u03b2-thalassemia major www.irct.ir\/trial\/41787"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0231|cit231","unstructured":"The influence of education FRIENDS on anxiety and loneliness in children with major thalassemia (8-18 Years Old) in Golestan province in 2019 en.irct.ir\/trial\/45400"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0232|cit232","unstructured":"Investigating the effect of religious education in thalassemia en.irct.ir\/trial\/52675"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0233|cit233","unstructured":"Combination iron chelation therapy clinicaltrials.gov\/ct2\/show\/NCT00004982"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0234|cit234","unstructured":"Study to evaluate treatment compliance, efficacy and safety of an improved deferasirox formulation (granules) in pediatric patients (2-<18 years old) with iron overload clinicaltrialsregister.eu\/ctr-search\/trial\/2013-004739-55\/HU"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0235|cit235","unstructured":"Study to evaluate treatment compliance, efficacy and safety of an improved deferasirox formulation (granules) in pediatric patients (2-<18 years old) with iron overload clinicaltrials.gov\/ct2\/show\/NCT02435212"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0236|cit236","unstructured":"Wali Y Cruz MC Charoenkwan P Bachir J Aushev A Compliance and clinical benefit of deferasirox granule formulation vs dispersible tablets in pediatric patients with transfusional iron overload: results from the phase II CALYPSO study library.ehaweb.org\/eha\/2019\/24th\/266299\/ali.t.taher.compliance.and.clinical.benefit.of.deferasirox.granule.formulation.html; European Hematology Association (EHA24); online conference; 2019 Jun 14 2019"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0237|cit237","unstructured":"To assess compliance, efficacy and satisfaction with two different formulation of deferasirox in patients with transfusion-dependent beta-thalassemia en.irct.ir\/trial\/16826"},{"issue":"21","key":"10.1002\/14651858.CD012349.pub3-BIB0238|cit238","first-page":"6","article-title":"A randomized controlled trial studying the effectiveness of group medical appointments on self-efficacy and adherence in sickle cell disease (TEAM study): study protocol","volume":"16","author":"Madderom","year":"2016","journal-title":"BMC Hematology"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0239|cit239","unstructured":"A randomized trial evaluaTing the Effects of group medical AppointMents on self-efficacy and adherence in Sickle Cell Disease (TEAM study) trialsearch.who.int\/Trial2.aspx?TrialID=NTR4750"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0240|cit240","unstructured":"Pilot evaluation of a motivational interviewing intervention targeting adherence behaviors in youth with sickle cell disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04877054"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1477-7525-4-73","article-title":"The impact of iron overload and its treatment on quality of life: results from a literature review","volume":"4","author":"Baladi","year":"2006","journal-title":"Health and Quality of Life Outcomes"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0242|cit242","unstructured":"American Pharmacists Association National Association of Chain Drug Stores Foundation Medication therapy management in community pharmacy practice: core elements of an MTM service (version 2.0) American Pharmacists Association 2008 24"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0243|cit243","unstructured":"All-Party Parliamentary Group on Sickle Cell and Thalassaemia (APPG) Sickle cell disease and thalassaemia: a health check http:\/\/ukts.org\/pdfs\/awareness\/appg.pdf"},{"issue":"6","key":"10.1002\/14651858.CD012349.pub3-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjh.12825","article-title":"Current approach to iron chelation in children","volume":"165","author":"Aydinok","year":"2014","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD012349.pub3-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2214.2004.00478.x","article-title":"A literature review to identify interventions to improve the use of medicines in children","volume":"30","author":"Costello","year":"2004","journal-title":"Child: Care, Health and Development"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0246|cit246","unstructured":"Covidence systematic review software Veritas Health Innovation 2017"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0247|cit247","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0248|cit248","unstructured":"EPOC Resources for review authors http:\/\/epoc.cochrane.org\/epoc-specific-resources-review-authors"},{"issue":"8","key":"10.1002\/14651858.CD012349.pub3-BIB0249|cit249","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004450.pub3","article-title":"Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia","author":"Fisher","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/515S1a","article-title":"Sickle-cell disease","volume":"515","author":"Gravitz","year":"2014","journal-title":"Nature"},{"issue":"6 S4","key":"10.1002\/14651858.CD012349.pub3-BIB0251|cit251","first-page":"S298","article-title":"Sickle cell disease in Africa. A neglected cause of early childhood mortality","volume":"41","author":"Grosse","year":"2011","journal-title":"American Journal of Preventive Medicine"},{"issue":"10","key":"10.1002\/14651858.CD012349.pub3-BIB0252|cit252","first-page":"1022","article-title":"A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease","volume":"10","author":"Beach","year":"2009","journal-title":"Journal of the National Medical Association"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0253|cit253","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0254|cit254","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0255|cit255","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0256|cit256","unstructured":"Li T Higgins JP Deeks JJ Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, \u00a0editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"6","key":"10.1002\/14651858.CD012349.pub3-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2471\/BLT.06.036673","article-title":"Global epidemiology of haemoglobin disorders and derived service indicators","volume":"86","author":"Modell","year":"2008","journal-title":"Bulletin of the World Health Organization"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0258|cit258","unstructured":"National Collaborating Centre for Mental Health Depression in adults with a chronic physical health problem: treatment and management. Clinical guideline [CG91] www.nice.org.uk\/guidance\/cg91"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0259|cit259","unstructured":"The National Collaborating Centre for Primary Care Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. NICE Guideline CG76 https:\/\/www.nice.org.uk\/guidance\/cg76"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0260|cit260","unstructured":"National Institute for Health and Care Excellence Depression in adults with chronic physical health problem: recognition and management. NICE guideline CG91 www.nice.org.uk\/guidance\/cg91"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0261|cit261","unstructured":"NICE National Institute for health and Care Excellence Sickle cell disease http:\/\/cks.nice.org.uk\/sickle-celldisease#!backgroundsub:3"},{"issue":"8","key":"10.1002\/14651858.CD012349.pub3-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12325-008-0085-z","article-title":"Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload","volume":"25","author":"Payne","year":"2008","journal-title":"Advances in Therapy"},{"issue":"9861","key":"10.1002\/14651858.CD012349.pub3-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(12)61229-X","article-title":"Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates","volume":"381","author":"Piel","year":"2012","journal-title":"Lancet"},{"issue":"20","key":"10.1002\/14651858.CD012349.pub3-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMra1404415","article-title":"The \u03b1-thalassemias","volume":"371","author":"Weatherall","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/515S2a","article-title":"Epidemiology: a moving target","volume":"515","author":"Pleasants","year":"2014","journal-title":"Nature"},{"issue":"9757","key":"10.1002\/14651858.CD012349.pub3-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0267|cit267","unstructured":"Reeves BC Deeks JJ Higgins JP Shea B Tugwell P Wells GA Chapter 24: Including non-randomized studies on intervention effects. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0268|cit268","unstructured":"Review Manager (RevMan) The Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"8","key":"10.1002\/14651858.CD012349.pub3-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s12325-010-0049-y","article-title":"An instrument assessing satisfaction with iron chelation therapy: psychometric testing from an open-label clinical trial","volume":"27","author":"Rofail","year":"2010","journal-title":"Advances in Therapy"},{"issue":"11","key":"10.1002\/14651858.CD012349.pub3-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1056\/NEJMra050436","article-title":"\u03b2-Thalassemia","volume":"353","author":"Rund","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub3-BIB0271|cit271","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007768.pub3","article-title":"Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews","author":"Ryan","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0272|cit272","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0273|cit273","unstructured":"Sterne JAC Egger M Moher D on behalf of the Cochrane Bias Methods Group Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0274|cit274","unstructured":"Sterne JA Higgins JP Reeves BC on behalf of the development group for ROBINS-I ROBINS-I: a tool for assessing Risk Of Bias In Non-randomized Studies of Interventions, Version 7 March 2016 www.riskofbias.info"},{"issue":"9","key":"10.1002\/14651858.CD012349.pub3-BIB0275|cit275","first-page":"1187","article-title":"Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004","volume":"91","author":"Telfer","year":"2006","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"41","DOI":"10.53841\/bpscpf.2013.1.246.41","article-title":"Implementing the NICE clinical guideline 91 ('Depression in adults with a chronic physical health problem') in a haematology department","volume":"246","author":"Thomas","year":"2013","journal-title":"Clinical Psychology Forum"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1477-7525-10-148","article-title":"Beliefs about chelation among thalassemia patients","volume":"10","author":"Trachtenberg","year":"2012","journal-title":"Health and Quality of Life Outcomes"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1007\/s11136-014-0671-2","article-title":"Relationship among chelator adherence, change in chelators, and quality of life in thalassemia","volume":"23","author":"Trachtenberg","year":"2014","journal-title":"Quality of Life Research"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0279|cit279","unstructured":"United Kingdom Thalassaemia Society Standards for the clinical care of children and adults with thalassaemia in the UK UK Thalassaemia Society 2008 2nd edition 120"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3111\/13696998.2015.1117979","article-title":"Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia","volume":"19","author":"Vekeman","year":"2016","journal-title":"Journal of Medical Economics"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub3-BIB0281|cit281","first-page":"254","article-title":"Medication compliance research","volume":"3","author":"Wertheimer","year":"2003","journal-title":"Journal of Applied Research in Clinical and Experimental Therapeutics"},{"key":"10.1002\/14651858.CD012349.pub3-BIB0282|cit282","unstructured":"World Health Organization Adherence to long-term therapies: Evidence for action WHO 2003 194"},{"issue":"10","key":"10.1002\/14651858.CD012349.pub3-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease:summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD012349.pub3-BIB0284|cit284","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012349","article-title":"Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia","author":"Fortin","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD012349.pub3-BIB0285|cit285","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012349.pub2","article-title":"\u00a0Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia","author":"Fortin","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T21:21:18Z","timestamp":1729027278000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012349.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":285,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012349.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,6]]}}}